Clinical characteristics.

Nonsyndromic disorders of testicular development are a group of conditions characterized by the following:

• A generally normal physical examination with absence of clinical findings involving organ systems other than the reproductive organs
• A normal 46,XY karyotype by conventional staining
• External genitalia that range from ambiguous to normal female
• Internal genitalia that range from absent müllerian structures to a fully developed uterus and fallopian tubes
• Gonads that are characterized as normal testis, ovotestis, dysgenetic testis, or streak

Based on the particular features seen in any given individual, the clinical diagnosis may be designated as 46,XY disorder of sex development (DSD) or 46,XY complete gonadal dysgenesis (CDG).

Diagnosis/testing.

Nonsyndromic 46,XY DSD and 46,XY CGD must be distinguished from syndromic forms, in which additional organ systems, growth, and cognitive development may also be affected. Biallelic pathogenic variants in DHH, heterozygous pathogenic variants in MAP3K1 and NR5A1, hemizygous pathogenic variants in SRY, hemizygous duplication of NR0B1, and heterozygous deletion of DMRT1 are causative of nonsyndromic 46,XY disorders of testicular development.

Genetic counseling.

Nonsyndromic disorders of testicular development can be inherited in a sex-limited autosomal recessive (DHH), sex-limited autosomal dominant (MAP3K1, NR5A1, and heterozygous deletion of DMRT1), Y-linked (SRY), or X-linked manner (hemizygous duplication of NR0B1). Genetic counseling and risk assessment depend on determination of the specific cause and the sex chromosome complement of the individual who harbors the pathogenic variant(s).

Management.

Treatment of manifestations: Evaluation and long-term management is best performed at a center with an interdisciplinary care team (including clinical geneticists, endocrinologists, surgeons, and mental health professionals) experienced in the diagnosis and management of DSD; all individuals should receive a sex of rearing; surgical decisions should be made after detailed discussion with the family regarding risks, benefits, and limitations of any proposed surgery; surgical intervention (hypospadias repair, orchiopexy, scrotoplasty, and phalloplasty in males and clitoroplasty, vaginoplasty, and urogenital sinus mobilization in females) should focus on functionality; whenever possible, removal of tissue and irreversible procedures should be avoided; streak gonads and nonfunctional dysgenetic gonads should be removed to decrease the risk for gonadoblastoma; dysgenetic gonads with residual function that are not removed require tumor surveillance; if gonads are retained, surveillance for the development of contrasexual puberty is warranted if sex of rearing is discordant with gonadal sex; sex steroid therapy (testosterone in males and estrogen or estrogen/progesterone in females) is important for the development of secondary sexual characteristics and for normal adolescent bone mass accrual; 46,XY individuals with a heterozygous pathogenic variant in NR5A1 should be monitored for adrenal insufficiency; most affected individuals are infertile, although assisted reproductive technologies may help achieve pregnancy in some cases.

Surveillance: Regular follow up with an interdisciplinary DSD team including endocrinology, genetics, obstetrics/gynecology, psychology, and urology.

Nomenclature

The nomenclature for disorders of sex development (DSD) was revised in 2006 to reflect the genetic causes and pathogenesis of these conditions [Houk et al 2006]:

• The term “disorders of sex development” has replaced the term “intersex.”
• The term “46,XY DSD” has replaced the following terms:
  • Male pseudohermaphrodite
  • Undervirilization of an XY male
  • Undermasculinization of an XY male
  • Mixed gonadal dysgenesis
  • Partial gonadal dysgenesis
• The term “46,XY CGD” has replaced the terms “46,XY sex reversal” and “46,XY female.”
• The term “46,XY ovotesticular DSD” has replaced “46,XY true hermaphrodite.”

Chromosome Analysis

One genetic testing strategy is to perform a karyotype using conventional staining methods of a sufficient number of cells to detect mosaicism for sex chromosome aneuploidy (i.e., 45,X/46,XY) and fluorescence in situ hybridization (FISH) for the presence of SRY.

Another genetic testing strategy is to perform a chromosomal microarray (CMA), as this will determine the sex chromosome complement, evaluate for the presence or absence of SRY, and screen for deletion/duplication syndromes in which individuals may have genital anomalies within the DSD spectrum (see Table 1 and Conditions Not Discussed in the GeneReview). If the karyotype is already known, CMA may still be pursued, particularly for individuals in whom a syndromic diagnosis is being considered.

• Note: (1) If the individual has a 46,XY chromosome complement but is SRY negative, the cause of the individual’s nonsyndromic disorder of testicular development has been determined. (2) If CMA detects a deletion of SRY, a limited karyotype can be considered to determine if the deletion was caused by a translocation or a complex rearrangement of genetic material.

Molecular Genetic Testing

Molecular testing approaches can include single-gene testing, use of a multigene panel, and more comprehensive genomic testing.

Single-gene testing. Perform serial single-gene testing of the first four genes listed in Table 1 based on the individual’s clinical findings and/or the order in which pathogenic variants most commonly occur.

• If no pathogenic variants are identified in these four genes, gene-targeted deletion/duplication analysis of NR0B1 may be considered.
• If gene-targeted deletion/duplication analysis of NR0B1 is normal:
  • Chromosomal microarray (if not performed already) may be considered to screen for small deletions of 9p24 including DMRT1.
  • Gene-targeted deletion/duplication analysis of DMRT1 may be considered if chromosomal microarray was completed previously and was non-diagnostic.

A multigene panel that includes DHH, MAP3K1, NR5A1, SRY and other genes of interest (see Conditions Not Discussed in the GeneReview) may also be considered. Note: The genes included in the panel and diagnostic sensitivity of the testing used for each gene vary by laboratory and over time.

For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

More comprehensive genomic testing (when available) including exome sequencing or genome sequencing may be considered if single gene testing (and/or use of a multi-gene panel that includes the genes in Table 1) fails to confirm a diagnosis in an individual with features of a nonsyndromic disorder of testicular development. Some experts advocate using exome sequencing as second-line testing after a normal CMA [Barseghyan et al 2015]. For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Mode of Inheritance

Nonsyndromic disorders of testicular development can be inherited in a sex-limited autosomal recessive, sex-limited autosomal dominant, Y-linked, or X-linked manner depending on the gene involved:

• Sex-limited autosomal recessive inheritance: mutation of DHH
• Sex-limited autosomal dominant inheritance: mutation of MAP3K1 or NR5A1; deletion of 9p24 including DMRT1
• Y-linked inheritance: mutation of SRY
• X-linked inheritance: duplication of NR0B1

Risk to Family Members – Sex-Limited Autosomal Recessive Inheritance

Parents of a proband

• The parents of an individual with DHH-related autosomal recessive 46,XY complete gonadal dysgenesis (CGD) are obligate heterozygotes.
• Heterozygotes (carriers) are usually asymptomatic.

Sibs of a proband

• At conception, each sib of an affected individual has a 25% chance of having biallelic pathogenic variants, a 50% chance of being heterozygous for a DHH pathogenic variant, and a 25% chance of being unaffected and not heterozygous. XY sibs with biallelic pathogenic variants will have clinical features.
• Heterozygotes are usually asymptomatic.

Offspring of a proband

• Individuals with sex-limited autosomal recessive 46,XY nonsyndromic disorder of testicular development are frequently unable to reproduce.
• If ART allows individuals with a sex-limited autosomal recessive nonsyndromic disorder of testicular development to have children, all offspring will be heterozygous for a pathogenic variant in DHH and will therefore be unaffected.

Other family members. Each sib of the proband’s parents is at a 50% risk of being heterozygous for a DHH pathogenic variant.

Carrier (heterozygote) detection. Carrier testing for at-risk relatives requires prior identification of the DHH pathogenic variants in the family.

Risk to Family Members – Sex-Limited Autosomal Dominant Inheritance

Parents of a proband

• Pathogenic variants in MAP3K1 and NR5A1 and heterozygous deletion involving DMRT1 are inherited in a sex-limited autosomal dominant manner. In general, individuals with a 46,XX chromosome complement and a heterozygous MAP3K1 or NR5A1 pathogenic variant or heterozygous deletion of DMRT1 do not show clinical findings; however, some women with a heterozygous pathogenic variant in NR5A1 develop primary ovarian insufficiency [El-Khairi & Achermann 2012].
• Individuals with a MAP3K1 or NR5A1 heterozygous pathogenic variant or a heterozygous deletion in DMRT1 may have inherited the genetic variant from their mother or they may have a de novo variant.
• Recommendations for the evaluation of mother of a proband with an apparent de novo genetic variant include testing for the variant identified in the proband.
• The family history of some individuals diagnosed with sex-limited autosomal dominant nonsyndromic disorder of testicular development may appear to be negative because of milder phenotypic presentation in a parent or the appearance of reduced penetrance due to the sex-limited expression of the genetic variant. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.
• If the genetic variant found in the proband cannot be detected in the leukocyte DNA of either parent, possible explanations include a de novo variant in the proband or germline mosaicism in a parent (the incidence of germline mosaicism is unknown).

Sibs of a proband. The risk to the sibs of the proband depends on the genetic status of the proband’s parents and the sex chromosome complement of the sib:

• If a parent of the proband has a genetic variant, the risk to XY sibs is 50%. 46,XX sibs who inherit the variant are generally unaffected but would be at increased risk of having an affected child. 46,XX individuals with a heterozygous NR5A1 pathogenic variant may be at risk for primary ovarian insufficiency [El-Khairi & Achermann 2012].
• The sibs of a proband with clinically unaffected parents are still at increased risk for an autosomal dominant nonsyndromic disorder of testicular development because of the sex-limited nature of the condition.
• If the MAP3K1 or NR5A1 pathogenic variant or DMRT1 deletion found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism.

Offspring of a proband

• Individuals with a sex-limited autosomal dominant nonsyndromic disorder of testicular development frequently are unable to reproduce, particularly if they have a 46,XY chromosome complement. Some pathogenic variants in NR5A1 may allow for male fertility but assisted reproductive technologies (ART) may be needed.
• If ART allows individuals with a sex-limited autosomal dominant nonsyndromic disorder of testicular development to have children, each child would have a 50% chance of inheriting the pathogenic variant. 46,XY offspring would show clinical features. 46,XX offspring would generally be unaffected, although some 46,XX individuals with a heterozygous NR5A1 pathogenic variant could be at risk for primary ovarian insufficiency.

Other family members. The risk to other family members depends on the genetic status of the proband's parents: if a parent is affected or has a MAP3K1 or NR5A1 heterozygous pathogenic variant or a heterozygous DMRT1 deletion, his or her family members may be at risk.

Risk to Family Members – Y-Linked Inheritance

Parents of a proband

• Most individuals with an SRY-related nonsyndromic disorder of testicular development have a de novo pathogenic variant.
• In rare cases, individuals with an SRY-related nonsyndromic disorder of testicular development inherited the SRY pathogenic variant from their father. In these cases:
  • Either the father had somatic mosaicism (presumably including the germline) for an SRY pathogenic variant; or
  • The father had an SRY pathogenic variant penetrant only on certain genetic backgrounds [Cameron & Sinclair 1997, Sarafoglou & Ostrer 2000].
• The frequency of somatic mosaicism and SRY pathogenic variants with reduced penetrance is not known.
• The mother of an affected individual does not require evaluation/testing.

Sibs of a proband. The risk to XY sibs depends on the genetic status of the father (XX sibs are not at risk):

• Because probands with an SRY-related nonsyndromic disorder of testicular development usually have a de novo pathogenic variant, the risk to XY sibs of a proband is low.
• If the father of the proband has germline mosaicism or an SRY pathogenic variant with reduced penetrance, he may transmit an SRY pathogenic variant to XY sibs of the proband.

Offspring of a proband

• Individuals with an SRY pathogenic variant are unlikely to reproduce.
• If assisted reproductive technologies (ART) can allow individuals with an SRY pathogenic variant to have children, such individuals will pass the pathogenic variant to all of their XY offspring and none of their XX offspring.

Other family members. The risk to other family members depends on the genetic status of the proband's father.

Risk to Family Members – X-Linked Inheritance

Parents of a proband

• The father of an affected male will not have the disorder nor will he be hemizygous for the NR0B1 duplication; therefore, he does not require further evaluation/testing.
• In a family with more than one individual with an NR0B1-related nonsyndromic disorder of testicular development, the mother of an affected individual is an obligate carrier of the NR0B1 duplication. If a woman has more than one affected child and the NR0B1 duplication cannot be detected in her DNA, she has germline mosaicism.
• If a male is the only affected family member (i.e., a simplex case), the mother may be a heterozygote (carrier) or the affected male may have a de novo NR0B1 duplication, in which case the mother is not a carrier. Too few affected individuals have been reported to provide an accurate rate of de novo duplication; however, most of the affected individuals who have a small duplication inherited it from an unaffected carrier mother [Barbaro et al 2012].

Sibs of a proband. The risk to sibs depends on the genetic status of the mother:

• If the mother of the proband has an NR0B1 duplication, the chance of transmitting it in each pregnancy is 50%. 46,XY sibs who inherit the duplication will be affected; 46,XX sibs who inherit the duplication will be heterozygous and will usually not be affected.
• If the proband represents a simplex case (i.e., a single occurrence in a family) and if the NR0B1 duplication cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism.

Offspring of a proband

• Individuals with an NR0B1-related nonsyndromic disorder of testicular development are unlikely to reproduce.
• If ART enables individuals with an NR0B1 related nonsyndromic disorder of testicular development to have children, such individuals will pass the NR0B1 duplication to all of their XX offspring and none of their XY offspring.

Other family members. The proband's maternal aunts may be at risk of being heterozygotes (carriers) for the NR0B1 duplication and the aunts’ offspring, depending on their sex chromosome complement, may be at risk of being heterozygotes (carriers) for the NR0B1 duplication or of being affected.

Heterozygote (carrier) detection. Molecular genetic testing of at-risk female relatives to determine their genetic status requires prior identification of the NR0B1 duplication in the proband.

Related Genetic Counseling Issues

Family planning

• The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or are heterozygotes (carriers), or who are at increased risk of being heterozygotes (carriers) or affected.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing and Preimplantation Genetic Diagnosis

Once a DHH, MAP3K1, NR5A1, or SRY pathogenic variant(s), NR0B1 duplication, or 9p24 deletion involving DMRT1 has been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk are possible.

Treatment of Manifestations

A consensus statement on the management of disorders of sex development (DSDs) was developed under the sponsorship of the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology [Lee et al 2006] (full text). Further consensus guidelines for the care of children with DSD were developed by the Texas Children’s Hospital [Douglas et al 2010] (full text) and others [Parisi et al 2007] (full text).

Evaluation and long-term management should be received at a center with an interdisciplinary care team (including clinical geneticists, endocrinologists, surgeons, and mental health professionals) experienced in the diagnosis and management of DSDs

The general concepts of care include the following.

Sex assignment

• All individuals should receive a sex of rearing.
• Sex assignment in newborns with ambiguous genitalia should not be decided prior to an evaluation by experts.
• The choice of sex of rearing for individuals with 46,XY DSD is based on the underlying diagnosis, expert opinion, and parental beliefs [Houk et al 2006].

Surgical decisions should be made after detailed discussion with the family about risks, benefits, and limitations of any proposed surgery. Many surgeries are not medically necessary and thus, consideration should be given to delay the surgery in order to allow the affected individual to participate in the decision-making process.

• Surgical intervention in minors with DSD is controversial, particularly in those being reared female. Surgical intervention should focus on functionality; whenever possible, removal of tissue and irreversible procedures should be avoided.
• When male sex of rearing is chosen, surgical options may include hypospadias repair, orchiopexy, scrotoplasty, and phalloplasty. Removal of müllerian remnants may be considered.
• When female sex of rearing is chosen, surgical options may include clitoroplasty, vaginoplasty, and urogenital sinus mobilization. Vaginal dilation is also used for creation/expansion of the vagina.

Note: (1) No controlled clinical trials of the efficacy of different surgical techniques have been conducted. The long-term data regarding the quality of life and sexual function among those assigned male and female sex vary. (2) There is no consensus on the appropriate timing of the surgical procedures listed.

Management of gonads

• Streak gonads and dysgenetic gonads are at increased risk for gonadoblastoma and should be surgically removed if nonfunctional.
  If a dysgenetic gonad is located in the inguinal canal, it may be placed into the scrotum if results of an hCG stimulation test indicate some testicular function.
• Removal of gonads that are not consistent with the assigned sex of rearing is controversial.
  • Depending on the specific diagnosis, potentially functional gonads may be retained with appropriate surveillance for tumor development.
  • Routine surveillance for the development of contrasexual puberty is warranted in those whose sex of rearing is discordant with gonadal sex.
  • In some states, removal of potentially functional gonads in a minor requires a court order.

Hormone therapy. Sex steroid therapy is important for the development of secondary sexual characteristics and for normal adolescent bone mass accrual.

• If an individual is given a male sex assignment:
  • A short course of testosterone therapy may be used in infancy for treatment of micropenis (stretched penile length that is 2.5 standard deviations below the mean for age).
  • Testosterone therapy is typically required to initiate and sustain puberty.
• If an individual is given a female sex assignment:
  • Estrogen therapy is used to initiate breast development and puberty.
  • If the affected individual has a uterus, progesterone will be added once puberty has progressed in order to promote menstrual cycles.
• 46,XY individuals with a heterozygous pathogenic variant in NR5A1 may need to be managed for adrenal insufficiency.

Psychosocial aspects of care. As noted in the Lee et al consensus statement, “The initial contact with the parents of a child with a DSD is important, because first impressions from these encounters often persist…. Ample time and opportunity should be made for continued discussion with review of information previously provided.” [Lee et al 2006].

• Open communication with affected individuals and families, including their active participation in the decision-making process, is critical.
• Providers need to address the concerns of the affected individual and family respectfully and in strict confidence.

Fertility

• Most individuals with nonsyndromic disorders of sex development are infertile due to dysgenetic or streak gonads. Some pathogenic variants in NR5A1 are associated with normal testicular development in individuals with a 46,XY chromosome complement, which may allow for fertility, although assisted reproductive technology may be required.
• Women with 46,XY DSD or 46,XY CGD with müllerian structures may become pregnant through oocyte donation.
• Surveillance

Regular follow up with an interdisciplinary DSD team including endocrinology, medical genetics, obstetrics/gynecology, psychology, and urology is indicated.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Published Guidelines/Consensus Statements

• Accord Alliance. DSD Guidelines. Available online. 2008. Accessed 10-10-17.
• Douglas G, Axelrad ME, Brandt ML, Crabtree E, Dietrich JE, French S, Gunn S, Karaviti L, Lopez ME, Macias CG, McCullough LB, Suresh D, Sutton VR. Consensus in Guidelines for Evaluation of DSD by the Texas Children's Hospital Multidisciplinary Gender Medicine Team. Available online. 2010. Accessed 10-10-17. [PMC free article: PMC2963131] [PubMed: 20981291]
• Houk CP, Hughes IA, Ahmed SF, Lee PA; Writing Committee for the International Intersex Consensus Conference Participants. Summary of consensus statement on intersex disorders and their management. International Intersex Consensus Conference. Available online. 2006. Accessed 10-10-17. [PubMed: 16882833]
• Lee PA, Houk CP, Ahmed SF, Hughes IA; International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Consensus Statement on Management of Intersex Disorders Pediatrics. Available online. 2006. Accessed 10-10-17. [PubMed: 16882788]
• Parisi MA, Ramsdell LA, Burns MW, Carr MC, Grady RE, Gunther DF, Kletter GB, McCauley E, Mitchell ME, Opheim KE, Pihoker C, Richards GE, Soules MR, Pagon RA. A Gender Assessment Team: experience with 250 patients over a period of 25 years. Available online. 2007. Accessed 10-10-17. [PubMed: 17575501]

Literature Cited

• Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet. 1999;22:125–6. [PubMed: 10369247]
• Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, Jameson JL. Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner. J Clin Endocrinol Metab. 2002;87:1829–33. [PubMed: 11932325]
• Barbaro M, Cicognani A, Balsamo A, Löfgren A, Baldazzi L, Wedell A, Oscarson M. Gene dosage imbalances in patients with 46,XY gonadal DSD detected by an in-house-designed synthetic probe set for multiplex ligation-dependent probe amplification analysis. Clin Genet. 2008;73:453–64. [PubMed: 18384427]
• Barbaro M, Cook J, Lagerstedt-Robinson K, Wedell A. Multigeneration Inheritance through Fertile XX Carriers of an NR0B1 (DAX1) Locus Duplication in a Kindred of Females with Isolated XY Gonadal Dysgenesis. Int J Endocrinol. 2012;2012:504904. [PMC free article: PMC3299259] [PubMed: 22518125]
• Barbaro M, Oscarson M, Schoumans J, Staaf J, Ivarsson SA, Wedell A. Isolated 46,XY gonadal dysgenesis in two sisters caused by a Xp21.2 interstitial duplication containing the DAX1 gene. J Clin Endocrinol Metab. 2007;92:3305–13. [PubMed: 17504899]
• Barseghyan H, Délot E, Vilain E. New genomic technologies: an aid for diagnosis of disorders of sex development. Horm Metab Res. 2015;47:312–20. [PubMed: 25970709]
• Baxter RM, Arboleda VA, Lee H, Barseghyan H, Adam MP, Fechner PY, Bargman R, Keegan C, Travers S, Schelley S, Hudgins L, Mathew RP, Stalker HJ, Zori R, Gordon OK, Ramos-Platt L, Pawlikowska-Haddal A, Eskin A, Nelson SF, Délot E, Vilain E. Exome sequencing for the diagnosis of 46,XY disorders of sex development. J Clin Endocrinol Metab. 2015;100:E333–44. [PMC free article: PMC4318895] [PubMed: 25383892]
• Biason-Lauber A, Konrad D, Meyer M, DeBeaufort C, Schoenle EJ. Ovaries and female phenotype in a girl with 46,XY karyotype and mutations in the CBX2 gene. Am J Hum Genet. 2009;84:658–63. [PMC free article: PMC2680992] [PubMed: 19361780]
• Cameron FJ, Sinclair AH. Mutations in SRY and SOX9: testis-determining genes. Hum Mutat. 1997;9:388–95. [PubMed: 9143916]
• Canto P, Söderlund D, Reyes E, Méndez JP. Mutations in the desert hedgehog (DHH) gene in patients with 46,XY complete pure gonadal dysgenesis. J Clin Endocrinol Metab. 2004;89:4480–3. [PubMed: 15356051]
• Douglas G, Axelrad ME, Brandt ML, Crabtree E, Dietrich JE, French S, Gunn S, Karaviti L, Lopez ME, Macias CG, McCullough LB, Suresh D, Sutton VR. Consensus in Guidelines for Evaluation of DSD by the Texas Children's Hospital Multidisciplinary Gender Medicine Team. Int J Pediatr Endocrinol. 2010;2010:919707. [PMC free article: PMC2963131] [PubMed: 20981291]
• El-Khairi R, Achermann JC. Steroidogenic factor-1 and human disease. Semin Reprod Med. 2012;30:374–81. [PMC free article: PMC5159746] [PubMed: 23044873]
• Hawkins JR, Taylor A, Goodfellow PN, Migeon CJ, Smith KD, Berkovitz GD. Evidence for increased prevalence of SRY mutations in XY females with complete rather than partial gonadal dysgenesis. Am J Hum Genet. 1992;51:979–84. [PMC free article: PMC1682856] [PubMed: 1415266]
• Houk CP, Hughes IA, Ahmed SF, Lee PA., Writing Committee for the International Intersex Consensus Conference Participants. Summary of consensus statement on intersex disorders and their management. International Intersex Consensus Conference. Pediatrics. 2006;118:753–7. [PubMed: 16882833]
• Ledig S, Hiort O, Scherer G, Hoffmann M, Wolff G, Morlot S, Kuechler A, Wieacker P. Array-CGH analysis in patients with syndromic and non-syndromic XY gonadal dysgenesis: evaluation of array CGH as diagnostic tool and search for new candidate loci. Hum Reprod. 2010;25:2637–46. [PubMed: 20685758]
• Lee PA, Houk CP, Ahmed SF, Hughes IA; International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Consensus Statement on Management of Intersex Disorders Pediatrics. 2006;118:e488-500. [PubMed: 16882788]
• Ostrer H. Disorders of sex development (DSDs): an update. J Clin Endocrinol Metab. 2014;99:1503–9. [PubMed: 24758178]
• Parisi MA, Ramsdell LA, Burns MW, Carr MC, Grady RE, Gunther DF, Kletter GB, McCauley E, Mitchell ME, Opheim KE, Pihoker C, Richards GE, Soules MR, Pagon RA. A Gender Assessment Team: experience with 250 patients over a period of 25 years. Genet Med. 2007;9:348–57. [PubMed: 17575501]
• Philibert P, Leprieur E, Zenaty D, Thibaud E, Polak M, Frances AM, Lespinasse J, Raingeard I, Servant N, Audran F, Paris F, Sultan C. Steroidogenic factor-1 (SF-1) gene mutation as a frequent cause of primary amenorrhea in 46,XY female adolescents with low testosterone concentration. Reprod Biol Endocrinol. 2010;8:28. [PMC free article: PMC2848664] [PubMed: 20302644]
• Quinonez SC, Park JM, Rabah R, Owens KM, Yashar BM, Glover TW, Keegan CE. 9p partial monosomy and disorders of sex development: review and postulation of a pathogenetic mechanism. Am J Med Genet A. 2013;161A:1882–96. [PubMed: 23824832]
• Sarafoglou K, Ostrer H. Clinical review 111: familial sex reversal: a review. J Clin Endocrinol Metab. 2000;85:483–93. [PubMed: 10690846]
• Tannour-Louet M, Han S, Corbett ST, Louet JF, Yatsenko S, Meyers L, Shaw CA, Kang SH, Cheung SW, Lamb DJ. Identification of de novo copy number variants associated with human disorders of sexual development. PLoS One. 2010;5:e15392. [PMC free article: PMC2964326] [PubMed: 21048976]
• Umehara F, Tate G, Itoh K, Yamaguchi N, Douchi T, Mitsuya T, Osame M. A novel mutation of desert hedgehog in a patient with 46,XY partial gonadal dysgenesis accompanied by minifascicular neuropathy. Am J Hum Genet. 2000;67:1302–5. [PMC free article: PMC1288570] [PubMed: 11017805]
• Veitia R, Ion A, Barbaux S, Jobling MA, Souleyreau N, Ennis K, Ostrer H, Tosi M, Meo T, Chibani J, Fellous M, McElreavey K. Mutations and sequence variants in the testis-determining region of the Y chromosome in individuals with a 46,XY female phenotype. Hum Genet. 1997;99:648–52. [PubMed: 9150734]
• White S, Ohnesorg T, Notini A, Roeszler K, Hewitt J, Daggag H, Smith C, Turbitt E, Gustin S, van den Bergen J, Miles D, Western P, Arboleda V, Schumacher V, Gordon L, Bell K, Bengtsson H, Speed T, Hutson J, Warne G, Harley V, Koopman P, Vilain E, Sinclair A. Copy number variation in patients with disorders of sex development due to 46,XY gonadal dysgenesis. PLoS One. 2011;6:e17793. [PMC free article: PMC3049794] [PubMed: 21408189]

Author History

Patricia Fechner, MD (2016-present)
Catherine E Keegan, MD, PhD (2016-present)
Lauren Mohnach, MS (2016-present)
Harry Ostrer, MD; New York University School of Medicine (2008-2016)

Author Notes

Website: www.mottchildren.org/conditions-treatments/peds-sex-development

Revision History

• 2 June 2016 (ma) Comprehensive update posted live; reconfigured as an overview
• 15 September 2009 (cd) Revision: deletion/duplication analysis no longer available clinically for NR0B1; FISH available
• 24 July 2008 (cd) Revision: testing for mutations in NR5A1 available clinically
• 21 May 2008 (me) Posted live
• 19 December 2007 (ho) Original submission